

Liver Center Annual Symposium 2018 Poster Session	
#	Abstract (presenter underlined)
1	A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis.
	Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X.
2	Dysregulation of hepatic homocysteine metabolism in liver-specific autophagy-deficient mice. <u>Kwon D</u> , Correia MA.
3	Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
	Kelley RK, Rodriguez-Lee M, Hwang J, Gordan JD, Nimeiri HS, Bocobo AG, Kircher S, Kanakemedala A, Mulcahy MF, Benson AB III, <u>Venook AP</u> .
4	Physical activity in cirrhotic patients and its association with mortality.
	<u>Lebsack A</u> , Shiboski SC, Lai JC.
5	The expression of a Y-linked proto-oncogene TSPY is associated with global DNA hypomethylation and is a potential biomarker for diagnosis and prognosis in hepatocellular carcinoma.
	<u>Kido T</u> , Lau C.
	A20 Restricts Necroptosis.
6	Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil SS, <u>Ma A</u> .
7	Deep Sequencing of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangio Carcinoma and Klatskin Tumors.
	Mattis DM, Joseph N, Yeh I, Talevich E, Onodera C, <u>Mattis AN</u> .
8	Modeling Fatty Liver from a Family with TM6SF2 E167K.
	Esteva-Font C, Castano D, Su T, Mattis AN.
9	Hepatitis C Successfully Infects Human Liver Organoids.
	Meyers N, Khalid M, Erickson A, Avanesyan L, Natarajan V, Hookway T, Muench M, Baron J, McDevitt T, Cooper S, Ott M.
10	Justifying non-standard exception requests for pediatric liver transplant candidates: An analysis of narratives submitted to the United Network for Organ Sharing, 2009-2014.
	Perito ER, Braun HJ, <u>Dodge JL</u> , Rhee S, Roberts JP.
11	Biomarkers associated with fatty liver are independent of visceral adiposity and differ by HIV status.
	Price JC, Wang R, Seaberg EC, Budoff MJ, Kingsley LA, Palella Jr FJ, Witt MD, Post WS, Thio CL.
	Testosterone Levels in Pre-Menopausal Women Are Independently Associated with Prevalent NAFLD in Midlife.
12	<u>Sarkar M</u> , Wellons M, Cedars M, VanWagner LB, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N.
13	Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
	Reid M, Ma Y, Scherzer R, Price JC, French AL, Plankey MW, Grunfeld C, <u>Tien PC.</u>
14	Predicting in vivo hepatic clearance from in vitro microsomal measures: A reexamination of basic concepts.
	Sodhi J, Bowman C, Benet LZ.

15	Regulation of Hepatic Gluconeogenesis by Angiopoietin-like 4 Fibrinogen-like Domain. <u>McQueen AE</u> , Yan K, Cheng J, Koliwad S, Wang JC.
16	Lipid Uptake and Metabolism in Intrahepatic Cholangiocarcinoma. Shihadih DS, Park HM, Nomura D, Chen X, Stahl A.
17	Hepatocyte plasticity underlies de novo bile duct formation in a mouse model of bile duct paucity. <u>Schaub JR</u> , Huppert KA, Cast AE, Chen F, Huppert SS, Willenbring H.
18	Hospitalizations for Autoimmune Hepatitis Disproportionately Affect Blacks and Latinos in the U.S. <u>Wen J</u> , Kohn MA, Wong RJ, Somsouk M, Khalili M, Maher JJ, <u>Tana MM</u> .
19	Autoimmune Hepatitis Disproportionately Affects People of Color. <u>Tana MM</u> , Holt EW, Wong RJ, Sewell JL, Khalili M, Maher JJ.
20	Hepatic Liver Receptor Homolog-1, a Key Regulator of Lipid Storage and Phospholipid Diversity. <u>Miranda DA</u> , Krause WC, Cazenave HEA, Shihadih DS, Stahl A, Wenk MR, Silver DL, Ingraham HA.
21	Hepatocyte-specific deletion of XBP1 in adult mice sensitizes them to diet-induced liver injury in a process involving RIDD. <u>Duwaerts CC</u> , Soon RK, Her C, Mattis AN, Maher JJ.
22	Improved survival across all interferon-treated patients, despite more cirrhosis among non-responders. <u>A Monto</u> , Shen H, Ryan JC.
23	Modeling Cystic Fibrosis Liver Disease Using Induced Pluripotent Stem Cell-Derived Cholangiocytes. <u>Castaño D</u> , Esteva-Font C,Su T, Mattis AN.
24	Laboratory Biomarkers of Frailty in Patients with Cirrhosis: From the Functional Assessment in Liver Transplantation (FrAILT) Study. <u>Huppert L</u> , Sinclair M, Lai JC.
25	Direct-acting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant waitlist dropout. <u>Huang AC</u> , Mehta N, Dodge JL, Yao FY, Terrault N.
26	Age- and HBV-dependent Gene Expression Patterns in a Mouse Model of Hepatitis B. Jespersen JM, Wang A, Gaggar A, Publicover J, Sigdel T, Cooper S, Sarwal M, Baron J.
27	Identifying a role for T cell therapy in treatment of chronic HBV disease using a mouse model. <u>Publicover J</u> , Nakagawa T, Johnson AJ, Erickson A, Goodsell A, Jespersen JM, Cooper S, Slanetz A, Baron JL.